The effect of SARS-CoV-2 variant on respiratory features and mortality.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 03 2023
Historique:
received: 04 05 2022
accepted: 16 03 2023
entrez: 19 3 2023
pubmed: 20 3 2023
medline: 22 3 2023
Statut: epublish

Résumé

SARS-CoV-2 (COVID-19) has caused over 80 million infections 973,000 deaths in the United States, and mutations are linked to increased transmissibility. This study aimed to determine the effect of SARS-CoV-2 variants on respiratory features, mortality, and to determine the effect of vaccination status. A retrospective review of medical records (n = 55,406 unique patients) using the University of California Health COvid Research Data Set (UC CORDS) was performed to identify respiratory features, vaccination status, and mortality from 01/01/2020 to 04/26/2022. Variants were identified using the CDC data tracker. Increased odds of death were observed amongst unvaccinated individuals and fully vaccinated, partially vaccinated, or individuals who received any vaccination during multiple waves of the pandemic. Vaccination status was associated with survival and a decreased frequency of many respiratory features. More recent SARS-CoV-2 variants show a reduction in lower respiratory tract features with an increase in upper respiratory tract features. Being fully vaccinated results in fewer respiratory features and higher odds of survival, supporting vaccination in preventing morbidity and mortality from COVID-19.

Identifiants

pubmed: 36934134
doi: 10.1038/s41598-023-31761-y
pii: 10.1038/s41598-023-31761-y
pmc: PMC10024278
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4503

Informations de copyright

© 2023. The Author(s).

Références

BMJ. 2020 Aug 3;370:m3001
pubmed: 32747332
Clin Nurs Res. 2022 Nov;31(8):1390-1398
pubmed: 36154716
JAMA. 2022 Sep 6;328(9):823-824
pubmed: 35921084
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Glob Health J. 2021 Mar;5(1):51-55
pubmed: 33585053
Med (N Y). 2022 Apr 8;3(4):262-268.e4
pubmed: 35313451
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
J Adv Nurs. 2022 Nov;78(11):3618-3628
pubmed: 36036199
Nature. 2022 Mar;603(7902):693-699
pubmed: 35062016

Auteurs

Thomas D Hughes (TD)

University of California, Irvine, Irvine, USA.

Ajan Subramanian (A)

University of California, Irvine, Irvine, USA.

Rana Chakraborty (R)

Mayo Clinic, Rochester, USA.

Shannon A Cotton (SA)

University of California, Irvine, Irvine, USA.

Maria Del Pilar Giraldo Herrera (MDPG)

University of California, Irvine, Irvine, USA.

Yong Huang (Y)

University of California, Irvine, Irvine, USA.

Natalie Lambert (N)

Indiana University, Bloomington, USA.

Melissa D Pinto (MD)

University of California, Irvine, Irvine, USA.

Amir M Rahmani (AM)

University of California, Irvine, Irvine, USA.

Carmen Josefa Sierra (CJ)

University of Miami, Coral Gables, USA.

Charles A Downs (CA)

University of Miami, Coral Gables, USA. cxd826@miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH